Clinical outcome of Guillain-Barré syndrome with various treatment methods and cost effectiveness: A study from tertiary care center in South India: Yashoda GBS Registry
- Author:
Jaydip Ray Chaudhuri
;
Suvarna Alladi
;
K Rukmini Mridula
;
Demudu Babu Boddu
;
MV Rao
;
C Hemanth
;
V Dhanalaxmi
;
J Mayurnath Reddy
;
S Manimala Rao, Banda Balaraju
;
Srinivasarao Bandaru
- Publication Type:Journal Article
- From:Neurology Asia
2014;19(3):263-270
- CountryMalaysia
- Language:English
-
Abstract:
Back ground and Objective: Both plasmapheresis and intra venous immunoglobulin (IVIG) are effective
for Guillain-Barré syndrome (GBS) but differ in cost and ease of administration. The aim of this study
was to evaluate and compare clinical outcome after treatment with IVIg and plasmapheresis in patients
with various GBS subtypes and assess their cost effectiveness. Methods: Thirty seven consecutive
GBS patients, recruited from May 2008 to September 2012, from Department of Neurology, Yashoda
hospital Hyderabad, underwent detailed clinical and electrophysiological assessment. Patients randomly
received either IVIG or plasmapheresis. Outcome was measured using change in mean motor power
and Hughes grade at discharge. Effectiveness and duration of hospital stay was compared with cost
effectiveness of both therapies. Results: Out of 37 patients; men were 23 (62.1%), mean age was
42.3 +14.1 years. Electro physiologically acute inflammatory demyelinating neuropathy (AIDP) was
most common (56.7%). Nineteen patients (51.3%) received IVIG and plasmapheresis was done in 18
(48.6%). Cost of plasmapheresis was significantly lower (mean USD 2,584.5 versus USD 4,385.3)
(p=0.01). At discharge, significant and similar improvement was noted in both groups although
duration of hospital stay was longer in plasmapheresis group Three patients (2 in plasmapheresis and
one in IVIG group) died.
Conclusion: In developing countries, plasmapheresis may be a better option in treatment of GBS.
- Full text:P020150630453099603021.pdf
